Form 4: Candel Therapeutics CFO Boosts Stake Through Direct Offering
Insider Transaction Report
Candel Therapeutics, Inc.'s Chief Financial Officer, Charles Schoch, acquired 5,353 shares of common stock at $4.67 per share through a registered direct offering.
Summary
- Charles Schoch, the Chief Financial Officer of Candel Therapeutics, Inc. (CADL), acquired 5,353 shares of the company's common stock.
- The transaction occurred on June 25, 2025, with the shares purchased at a price of $4.67 per share.
- These shares were acquired directly from the Issuer as part of a registered direct offering, pursuant to the terms of a Securities Purchase Agreement dated June 23, 2025.
- Following this acquisition, Mr. Schoch's beneficial ownership in Candel Therapeutics, Inc. totals 43,391 shares of common stock.
Sentiment
Score: 7
Explanation: The acquisition of shares by the Chief Financial Officer suggests confidence in the company's valuation and future prospects, which is generally viewed positively by the market.
Positives
- The acquisition of shares by the Chief Financial Officer signals management's confidence in the company's future prospects and valuation.
- The transaction was part of a registered direct offering, indicating a structured and transparent capital raising or share issuance event for the company.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- The Chief Financial Officer, Charles Schoch, acquired shares directly from Candel Therapeutics, Inc. as part of a registered direct offering, which constitutes a related party transaction.
Stakeholder Impact
- Shareholders: Insider buying can be interpreted as a positive signal, potentially increasing investor confidence in the company's future performance.
- Company: The registered direct offering likely provided additional capital to the company, strengthening its financial position.
Key Dates
| Date | Description |
|---|---|
| 06/23/2025 | Date of the Securities Purchase Agreement related to the registered direct offering. |
| 06/25/2025 | Date of the transaction where Charles Schoch acquired common stock. |
| 06/26/2025 | Date the Form 4 was signed and filed with the SEC. |
Recommendation
holdKeywords
Candel Therapeutics, CADL, Charles Schoch, Chief Financial Officer, Insider Trading, Form 4, Share Acquisition, Direct Offering, Common Stock, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.